Onco Data Hub

Unicancer innovates and creates, in partnership with Roche, the first building block of a consortium to create the French reference platform in oncology for the use of therapies in real life.

Unicancer and Roche are combining their expertise and launching the OncoDataHub (ODH), to accelerate the production and use of real-life data in cancer, and to make available to the players in the healthcare system the first observatory for drugs and innovation in oncology

ODH will meet the need for studies on the management and use of health products in order to improve patient care. 

The real-life data revolution

Real-life data are generated during care and correspond to the usual ways in which patients are managed. They thus reflect current practice.

They are complementary to data from clinical trials and make it possible to assess the extent to which the results on biological efficacy and tolerance observed in clinical trials are verified in real life. Furthermore, they are essential for evaluating the effectiveness of therapeutic strategies applied to care.

The medical community, researchers and patients will benefit from the progress made possible by these data.  Institutional and public players will have additional information enabling them to better assess the cost-benefit ratio of treatments and thus better control healthcare expenditure while preserving the interests of patients.

A platform for the benefit of patients

Ultimately, the platform promises major advances for patients, regardless of the type of cancer they suffer from and at all stages of the disease, thanks to the opportunities offered by health data, big data and Artificial Intelligence.

By accelerating research into the use and management of healthcare products, it offers patients the opportunity to access innovative, increasingly personalised treatments.

Unicancer and the Roche laboratory intend to play a driving and pioneering role in this revolution already underway by providing, through ODH, a tool that will contribute decisively to future success in the fight against cancer.

Facilitating access to health data for as many people as possible

The ambition of the OncoDataHub is to make available to the actors of the health ecosystem (doctors, academic actors, laboratories, institutions) a set of longitudinal quality data, representative of the management of cancer patients in France.

• To offer doctors/researchers the opportunity to conduct research projects on innovative therapeutic strategies, particularly on specific populations, in conjunction with traditional clinical trials
• To guide medical practice and inform the decisions of health authorities through the evaluation of current therapeutic strategies
• To respond to industrial needs (clinical development, marketing, post-marketing) thanks to representative, up-to-date data
• To ensure an observatory mission of prescriptions and oncology therapeutic strategies in France
• Involve and better inform patients on the results obtained from their treatment data

At Roche, we have always had a collective vision of health data. The creation of the OncoDataHub in partnership with Unicancer is a concrete expression of this desire to open up and share with the healthcare ecosystem. It is this collaboration between all the players that we hope and pray for, to find more solutions, more quickly, for more patients.

Jean-François Brochard, President of Roche Pharma France

ODH use cases and audiences

The objective of the ODH platform is to enable immediate use cases in terms of describing treatment strategies, practices and target populations.

ODH: complementary expertise of Unicancer and Roche

The ESMÉ platform launched in 2014 by Unicancer, a forerunner in this field at the time: a unique device for collecting and analysing real-life data. It brings together anonymised longitudinal clinical, biological and therapeutic data from more than 70,000 patients in 3 active databases: bronchopulmonary cancer (32,000 patients), metastatic breast cancer (27,000 patients) and ovarian cancer (12,000 patients) and includes 39 partner institutions (CLCC/CHU/CH). This programme has already made it possible to address more than 100 research projects that have already led to around 100 scientific communications, including 30 publications. Of these, about 50 have been used in dossiers for the authorities in the context of evaluating the response to therapeutic strategies.

The PRM platform implemented by the Roche laboratory, which collects, thanks to its dedicated infrastructure, real-life data on the prescription of anti-cancer treatments. This data increases knowledge on the use of treatments and led in February 2019 to the implementation of a price agreement with the CEPS (Comité Economique des Produits de Santé) based on the real benefit of a treatment provided to patients. Initiated in 2014, the PRM project now includes more than 130 partner healthcare institutions (CLCC/CHU/CH/private) ensuring regional and national representation of the management of patients with HER2+ breast cancer (25,000 patients) and metastatic lung cancer (5,000 patients) in France.

The complementary know-how of the two parties involved, and the network of partner institutions they share, guarantee a rapid production launch of the ODH platform.

A consortium of institutions, private partners and patient representatives will be created to ensure the strategic steering of the platform’s developments. Non-standardised research projects requiring access to data will be submitted to a project evaluation committee and an independent ethics and deontology committee.

ODH will initially focus on breast and lung indications. Subsequently, the platform’s scope will be extended by integrating additional parameters to those initially defined, opening it up to other indications or matching it to national databases.

The challenge of collecting, storing and analysing health data is a major one for the ecosystem. In terms of its principle, scope and operation, ODH is a unique and innovative structured data warehouse, which aims to meet the need for rapid access to data, at a limited cost, for a large number of players

Jean-Marc Pinguet, Director of Personalized Medicine at Roche